X4 PHARMACEUTICALS, INC Goodwill, Impaired, Accumulated Impairment Loss
X4 PHARMACEUTICALS, INC (XFOR) had Goodwill, Impaired, Accumulated Impairment Loss of $9.76 million as of 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Goodwill and Other › Goodwill, Impaired, Accumulated Impairment Loss
us-gaap:GoodwillImpairedAccumulatedImpairmentLoss · last filed 2026-03-17
- 2025-12-31: Goodwill, Impaired, Accumulated Impairment Loss $9.76M.
- 2024-12-31: Goodwill, Impaired, Accumulated Impairment Loss $9.76M.
- 2023-12-31: Goodwill, Impaired, Accumulated Impairment Loss $9.76M.
- 2022-12-31: Goodwill, Impaired, Accumulated Impairment Loss $9.76M.
| Period end | Goodwill, Impaired, Accumulated Impairment Loss |
|---|---|
| 2025-12-31 | $9.76M 10-K · filed 2026-03-17 |
| 2024-12-31 | $9.76M 10-K · filed 2026-03-17 |
| 2023-12-31 | $9.76M 10-K · filed 2026-03-17 |
| 2022-12-31 | $9.76M 10-K · filed 2025-03-26 |
| 2021-12-31 | $9.76M 10-K · filed 2024-03-21 |
| 2020-12-31 | $0.00 10-K · filed 2024-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |